Policosanol for cholesterol: the Cuban trials that no one could reproduce

← Back to articles

Policosanol is one of the cleanest examples of an effect that depends on who ran the study. A large body of trials from a single Cuban source reported LDL reductions rivaling low-dose statins, but the well-controlled independent replications conducted outside that group — in Germany, the United States, and Canada — have found essentially no lipid-lowering effect. The supplement category still markets the original Cuban numbers.

What policosanol actually is

Policosanol is a mixture of long-chain primary aliphatic alcohols, predominantly octacosanol, derived originally from sugarcane wax. The proprietary Cuban preparation contains a specific ratio of C24–C34 alcohols. Other commercial sources use rice bran wax, beeswax, or wheat germ, with different alcohol profiles — so two bottles labelled "policosanol" need not contain the same thing. The "octacosanol" supplements sold for athletic endurance are essentially the same chemistry.

The Cuban trial dossier

From the 1990s onward, a single research group in Cuba produced the bulk of the policosanol literature: by 2006 there were more than 80 placebo-controlled or comparative trials, "performed mostly by a single research institute," reporting that policosanol at 5–40 mg/day lowered LDL cholesterol to a degree comparable with statins [1]. The trials were numerous, mostly positive, and reasonably sized, and together they built an attractive marketing narrative. The problem is not that any one of them is obviously wrong, but that almost the entire evidence base traces back to one source — exactly the situation independent replication exists to test.

The independent replications

When investigators outside that group tried to reproduce the result, the effect vanished. A rigorous German multicenter trial randomized 143 patients with hypercholesterolemia or combined hyperlipidemia to policosanol at 10, 20, 40, or 80 mg/day or placebo for 12 weeks. In none of the five groups did LDL fall more than 10% from baseline, there was no statistically significant difference from placebo at any dose, and a formal test for dose-dependency was non-significant; total cholesterol, HDL, triglycerides, and lipoprotein(a) were likewise unmoved [1]. A US trial directly compared policosanol 20 mg/day against atorvastatin 10 mg/day in 99 patients: atorvastatin cut total cholesterol by 27% and LDL by 35%, while policosanol changed neither cholesterol nor LDL versus baseline or placebo, and added nothing when combined with the statin. The authors concluded policosanol "should be added to the list of nutritional supplements lacking scientific validity" [2].

This pattern — a large, internally consistent body of positive trials from one centre that independent groups cannot reproduce — is a recognised warning sign in evidence appraisal. It does not by itself prove misconduct; differences in the extract, the population, the diet, or the assay can all matter. But when the divide falls so cleanly along the line of who conducted the study, the burden of proof shifts to the original claims, and in policosanol's case that burden has not been met by anyone working independently.

Following the mechanism — and finding nothing

The Cuban work attributed policosanol's effect to suppressed cholesterol synthesis, so a Canadian group at McGill tested that directly using isotope-labelled tracers. In hypercholesterolemic subjects given 10 mg/day, there was no significant change in LDL, no change in the rate of cholesterol synthesis, and no change in cholesterol absorption versus control [3]. The replication failure thus extends past the clinical endpoint to the proposed mechanism itself: independent labs could not find the lipid effect or the biochemical change that was supposed to cause it. The most economical explanations are methodological differences, or selective reporting, in the original single-source dossier.

A genuinely mixed footnote: blood pressure

To be fair to the molecule, not every non-Cuban result is null. A Korean randomized trial of Cuban-sourced policosanol in 84 prehypertensive adults reported reductions in systolic blood pressure (about 7–8% at 20 mg/day over 12 weeks) along with changes in lipid parameters [4]. This is a blood-pressure signal in a different population, not the headline cholesterol claim, and it does not rehabilitate policosanol as a lipid-lowering agent. It is worth noting only because it shows the picture is not perfectly binary — but the cholesterol case, the one that actually sells the product, remains unreplicated.

Athletic "octacosanol"

Octacosanol-enriched policosanol is also sold for endurance and recovery. Those trials are small and inconsistent, and any effect is plainly smaller than that of better-studied ergogenic aids such as caffeine, dietary nitrate, or creatine. There is no compelling efficacy case for athletic use.

Safety and bottom line

Safety, at least, is not the problem: across the independent trials policosanol was well tolerated up to 80 mg/day, with adverse events and liver-enzyme changes similar to placebo [1][2]. Its theoretical effect on platelets argues for some caution alongside anticoagulants, but clinically meaningful bleeding has not been a feature of the trials. The bottom line is about efficacy, not harm. Anyone seeking non-statin LDL reduction has options with reproducible evidence — soluble fiber, plant sterols, red yeast rice (with its own caveats), or, with a clinician, bempedoic acid. Policosanol is not one of them.

Sources

1. Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. "Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial." JAMA, 2006;295(19):2262–2269. PMID 16705107. DOI: 10.1001/jama.295.19.2262.
2. Cubeddu LX, Cubeddu RJ, Heimowitz T, Restrepo B, Lamas GA, Weinberg GB. "Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial." American Heart Journal, 2006;152(5):982.e1–982.e5. PMID 17070175. DOI: 10.1016/j.ahj.2006.08.009.
3. Kassis AN, Jones PJH. "Changes in cholesterol kinetics following sugar cane policosanol supplementation: a randomized control trial." Lipids in Health and Disease, 2008;7:17. PMID 18447941. DOI: 10.1186/1476-511X-7-17.
4. Park HJ, Yadav D, Jeong DJ, Kim SJ, Bae MA, Kim JR, Cho KH. "Short-Term Consumption of Cuban Policosanol Lowers Aortic and Peripheral Blood Pressure and Ameliorates Serum Lipid Parameters in Healthy Korean Participants: Randomized, Double-Blinded, and Placebo-Controlled Study." International Journal of Environmental Research and Public Health, 2019;16(5):809. PMID 30841655. DOI: 10.3390/ijerph16050809.
5. Pepping J. "Policosanol." American Journal of Health-System Pharmacy, 2003;60(11):1112–1115. PMID 12816020. DOI: 10.1093/ajhp/60.11.1112.